Printz M - Search Results

1

Modeling the subcutaneous pharmacokinetics of antibodies co-administered with rHuPH20.

Nolan RP, Printz MA. Nolan RP, et al. Among authors: printz ma. Clin Transl Sci. 2024 Apr;17(4):e13788. doi: 10.1111/cts.13788. Clin Transl Sci. 2024. PMID: 38561908 Free PMC article.

2

Impact of the COVID-19 pandemic on perceived access and quality of care in German people with parkinsonism.

van Munster M, Printz MR, Crighton E, Mestre TA, Pedrosa DJ; iCARE-PD Consortium. van Munster M, et al. Among authors: printz mr. Front Public Health. 2023 Apr 14;11:1091737. doi: 10.3389/fpubh.2023.1091737. eCollection 2023. Front Public Health. 2023. PMID: 37124823 Free PMC article.

3

Association between Parkinson's Disease Medication and the Risk of Lower Urinary Tract Infection (LUTI): A Retrospective Cohort Study.

Gremke N, Griewing S, Printz M, Kostev K, Wagner U, Kalder M. Gremke N, et al. Among authors: printz m. J Clin Med. 2022 Nov 29;11(23):7077. doi: 10.3390/jcm11237077. J Clin Med. 2022. PMID: 36498652 Free PMC article.

4

Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration.

Printz MA, Sugarman BJ, Paladini RD, Jorge MC, Wang Y, Kang DW, Maneval DC, LaBarre MJ. Printz MA, et al. AAPS J. 2022 Oct 20;24(6):110. doi: 10.1208/s12248-022-00757-3. AAPS J. 2022. PMID: 36266598

5

Association between anti-seizure medication and the risk of lower urinary tract infection in patients with epilepsy.

Gremke N, Printz M, Möller L, Ehrenberg C, Kostev K, Kalder M. Gremke N, et al. Among authors: printz m. Epilepsy Behav. 2022 Oct;135:108910. doi: 10.1016/j.yebeh.2022.108910. Epub 2022 Sep 14. Epilepsy Behav. 2022. PMID: 36115082

6

Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery.

Knowles SP, Printz MA, Kang DW, LaBarre MJ, Tannenbaum RP. Knowles SP, et al. Among authors: printz ma. Expert Opin Drug Deliv. 2021 Nov;18(11):1673-1685. doi: 10.1080/17425247.2021.1981286. Epub 2021 Sep 29. Expert Opin Drug Deliv. 2021. PMID: 34585991

7

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer.

Kang DW, Bittner B, Sugarman BJ, Zepeda ML, Printz MA. Kang DW, et al. Among authors: printz ma. PLoS One. 2021 Jul 22;16(7):e0254765. doi: 10.1371/journal.pone.0254765. eCollection 2021. PLoS One. 2021. PMID: 34292990 Free PMC article.

8

Recombinant human hyaluronidase PH20-mediated dermal spreading activity in mice is not altered by steroids, antihistamines, or salicylic acid.

Cowell JA, Printz MA, Thompson CB. Cowell JA, et al. Among authors: printz ma. Drug Metab Pers Ther. 2020 Dec 25. doi: 10.1515/dmpt-2020-0120. Online ahead of print. Drug Metab Pers Ther. 2020. PMID: 33780198

9

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers.

Printz MA, Dychter SS, DeNoia EP, Harrigan R, Sugarman BJ, Zepeda M, Souratha J, Kang DW, Maneval DC. Printz MA, et al. Curr Ther Res Clin Exp. 2020 Aug 19;93:100604. doi: 10.1016/j.curtheres.2020.100604. eCollection 2020. Curr Ther Res Clin Exp. 2020. PMID: 32963641 Free PMC article.

10

Development of stable liquid formulations for oligonucleotides.

Poecheim J, Graeser KA, Hoernschemeyer J, Becker G, Storch K, Printz M. Poecheim J, et al. Among authors: printz m. Eur J Pharm Biopharm. 2018 Aug;129:80-87. doi: 10.1016/j.ejpb.2018.05.029. Epub 2018 May 23. Eur J Pharm Biopharm. 2018. PMID: 29802983

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

192 results

Search Page